Glenmark Pharmaceuticals announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately USD 1.7 billion for calendar year 2017.

Shares of the company gained Rs 4.1, or 0.78%, to trade at  Rs 528.80 at the BSE (9.03 a.m., Thursday).